Cadila Healthcare renamed Zydus Lifesciences in new innovation-centric corporate branding

INDIA – Cadila Healthcare Ltd will be renamed Zydus Lifesciences Ltd as part of the company’s new innovation and care-focused corporate brand identity.

According to a press release, the company’s new brand identity combines two hearts in purple and teal colors to represent its commitment to science and innovation, as well as care and nurturing.

The Zydus group has announced its new brand identity with the listed entity of the group Cadila Healthcare Ltd, building on a rich legacy of over 70 years as a healthcare and innovation-driven company.

Heralding a bold new vision for the organization, Pankaj R Patel, Chairman, Zydus Lifesciences Ltd said, “We have always believed in evolving and transforming ourselves in the ongoing quest to bring patient-centric solutions driven by science and innovation.

“With differentiated approaches, we have been addressing healthcare challenges globally, creating healthier communities. Reaffirming this commitment, we will continue to unlock new possibilities that can impact lives and empower people with life-changing discoveries.”

Two hearts come together in the new logo to enclose the word ‘us’ at the center. The heart symbolizes the company’s openness.

The colors teal and purple represent the pillars of science and care, respectively. While the dynamic teal expresses Zydus’ dynamism and represents the company’s dedication to science, the purposeful purple represents the company’s dedication to care and nurturing.

According to the company release, the ‘us’ in the new Zydus logo represents all stakeholders, including employees, patients, doctors, investors, bankers, business partners, associates, and all those who are an integral part of Zydus’ journey.

Our new brand identity is a confluence of what we truly are. A global life sciences company driven by the purpose of delivering care and nurturance for the patients, backed by the power of innovation, science and cutting-edge technology.”

Zydus’ commitment to healthcare innovations

Since its inception, Zydus has been committed to finding novel ways to assist people with unmet healthcare needs. Many of the discoveries made by the group are first-in-India or first-in-the-world.

Zydus was the first Indian pharmaceutical company to bring a new chemical identity (NCE), ‘Lipaglyn,’ from the lab to the market to treat Diabetic Dyslipidemia.

Bilypsa is also the world’s first drug to be approved for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).

Malaria has been a scourge, and the world has been fighting this tropical disease that kills millions of people each year. Zydus is working with MMV to develop ZY19489, a potential single-dose, fast-acting malaria treatment.

Aside from that, ZYIL1, the company’s novel oral small molecule, is a potential NLRP3 inhibitor.

Apart from NCEs, Zydus has a strong pipeline of biologics and vaccines. ZyCoV-D, the world’s first Plasmid DNA Vaccine for human use, is also a result of Zydus’ innovation.

Twinrab is a novel biological entity that is the first of its kind for rabies post-exposure prophylaxis.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE